GeneDx Holdings Corp. (WGS)
| Market Cap | 1.57B -60.2% |
| Revenue (ttm) | 460.78M +14.6% |
| Net Income | -111.05M |
| EPS | -3.76 |
| Shares Out | 29.97M |
| PE Ratio | n/a |
| Forward PE | 52.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,123,560 |
| Open | 51.01 |
| Previous Close | 51.87 |
| Day's Range | 48.42 - 52.59 |
| 52-Week Range | 32.21 - 170.87 |
| Beta | 1.99 |
| Analysts | Strong Buy |
| Price Target | 82.00 (+56.58%) |
| Earnings Date | Nov 9, 2026 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Financial Performance
In 2025, GeneDx Holdings's revenue was $427.54 million, an increase of 39.97% compared to the previous year's $305.45 million. Losses were -$21.02 million, -59.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $82.0, which is an increase of 56.58% from the latest price.
News
GeneDx price target lowered to $66 from $103 at Craig-Hallum
Craig-Hallum analyst Bill Bonello lowered the firm’s price target on GeneDx (WGS) to $66 from $103 and keeps a Buy rating on the shares. While the firm continues to believe…
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.
GeneDx price target lowered to $65 from $95 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on GeneDx (WGS) to $65 from $95 and keeps an Overweight rating on the shares.
GeneDx price target lowered to $85 from $90 at BTIG
BTIG lowered the firm’s price target on GeneDx (WGS) to $85 from $90 and keeps a Buy rating on the shares. The company delivered Q3 top line results that matched…
GeneDx announces new research to be presented at NSGC Annual Conference
GeneDx (WGS) announced new research to be presented at the National Society of Genetic Counselors, NSGC, 2026 Annual Conference, November 11-14. Across four scientific posters and three educational se...
GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients.
GeneDx Holdings Earnings Call Transcript: Q3 2026
Q3 revenue reached $123.1M, with 72% adjusted gross margin and $8.6M adjusted net income. Guidance raised for margins and income as documentation controls temporarily slow reported volume; collection improvements are central to 2027 growth.
GeneDx Holdings Earnings release: Q3 2026
GeneDx Holdings released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
GeneDx Holdings Quarterly report: Q3 2026
GeneDx Holdings has published its Q3 2026 quarterly earnings report on November 9, 2026.
GeneDx Holdings Slides: Q3 2026
GeneDx Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 9, 2026.
GeneDx Reports Third Quarter 2026 Financial Results
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2026.
GeneDx, Mirum launch sponsored testing programs
GeneDx (WGS) announced a collaboration with Mirum (MIRM) to offer no-cost exome testing for eligible patients across three sponsored testing programs: cholestasis, early-onset cataracts, and peroxisom...
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.
Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results...
GeneDx enhances genome testing portfolio with long-read whole-genome sequencing
The company states: “GeneDx (WGS) announced plans to enhance its genome testing portfolio with long-read whole genome sequencing. Long-read sequencing analyzes longer stretches of DNA to identify comp...
GeneDx announces plans to enhance genome testing portfolio with lrWGS
GeneDx (WGS) announced plans to enhance its genome testing portfolio with long-read whole genome sequencing, lrWGS. Leveraging insights from GeneDx Infinity and decades of clinical interpretation, Gen...
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testi...
GeneDx advances clinical adoption of genomic medicine with 27 abstracts at ASHG
The company states: “GeneDx (WGS) announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are adva...
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the America...
GeneDx presents new findings on genomic newborn screening at ICoNS 2026
GeneDx (WGS) announced new findings to be presented at the International Consortium on Newborn Sequencing, ICoNS, October 7-8 in Boston, demonstrating progress toward making genomic newborn screening ...
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026.
GeneDx to introduce Easy Order at AAP 2026
GeneDx (WGS) announced it will introduce Easy Order at the 2026 American Academy of Pediatrics National Conference & Exhibition, October 2-6 in San Diego. The new streamlined experience makes it…
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
GeneDx price target raised to $83 from $74 at Guggenheim
Guggenheim raised the firm’s price target on GeneDx (WGS) to $83 from $74 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for select…